2. Search Result
Search Result
Results for "

blood-stage parasites

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0148
    Risedronic acid
    2 Publications Verification

    Risedronate

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid
  • HY-B0119
    Risedronic acid sodium
    2 Publications Verification

    Risedronate sodium

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
    Risedronic acid sodium
  • HY-12912
    KDU691

    		PI4K Parasite Infection
    KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites .
    KDU691
  • HY-108024A
    Ganaplacide hydrochloride

    KAF156 hydrochloride; GNF156 hydrochloride

    		 Parasite Infection
    Ganaplacide (KAF156) hydrochloride is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide hydrochloride is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide hydrochloride is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .
    Ganaplacide hydrochloride
  • HY-B1036
    Decoquinate

    		Parasite Infection
    Decoquinate is an orally active, selective inhibitor of the mitochondrial bc1 complex, targeting Eimeria spp. sporozoites and first generation schizonts, and Plasmodium spp. Decoquinate inhibits electron transfer by competitively binding to the mitochondrial cytochrome b system, blocking the parasite's energy metabolism, thereby inhibiting its development and reproduction. Decoquinate has significant anticoccidial activity, preventing intestinal damage and improving host growth performance, and also has inhibitory effects on the liver and blood stages of Plasmodium. Decoquinate is mainly used in veterinary research to prevent and treat coccidiosis in ruminants and poultry .
    Decoquinate
  • HY-151574
    PfGSK3/PfPK6-IN-1

    		Ser/Thr Kinase Parasite GSK-3 Infection
    PfGSK3/PfPK6-IN-1 is a dual Plasmodium serine/threonine kinase inhibitor, with an IC50 of 97 nM against PfGSK3 and 8 nM against PfPK6 of Plasmodium falciparum. PfGSK3/PfPK6-IN-1 inhibits the proliferation of blood-stage parasites of Plasmodium falciparum 3D7. PfGSK3/PfPK6-IN-1 shows low cytotoxicity to hepatocytes at a concentration of 200 nM, and reduces cell viability at a concentration of 2 μM. PfGSK3/PfPK6-IN-1 is applicable to malaria-related research .
    PfGSK3/PfPK6-IN-1
  • HY-129651
    SHMT-IN-1

    		SHMT Infection
    SHMT-IN-1 is a Plasmodium falciparum Serine Hydroxymethyltransferase (PfSHMT) inhibitor with an IC50 of 350 nM. SHMT-IN-1 can be used for the research of malaria .
    SHMT-IN-1
  • HY-111817
    ACT-451840

    		Parasite Infection
    ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial .
    ACT-451840
  • HY-17656
    C3361

    		Parasite Infection
    C3361 is a moderate specific Plasmodium falciparum hexose transporter 1 (PfHT1) and Plasmodium berghei hexose transporter 1 (PbHT1) inhibitor with Ki values of 8.6 and 9.4 μM. C3361 inhibits TgGT1 with a Ki of 82 μM. C3361 attenuates hepatic (IC50 = 15 μM) and ookinete development of P. berghei. C3361 can suppress the growth of blood-stage parasites. C3361 can be used for the research of infection, such as malaria .
    C3361
  • HY-B0148R
    Risedronic acid (Standard)

    Risedronate (Standard)

    		 Parasite Reference Standards Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
    Risedronic acid (Standard)
  • HY-B0148S
    Risedronic acid-d4

    Risedronate-d4

    		 Isotope-Labeled Compounds Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid-d4
  • HY-108024
    Ganaplacide

    KAF156; GNF156

    		 Parasite Infection
    Ganaplacide (KAF156) is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .
    Ganaplacide
  • HY-120924
    BRD9185

    		Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite Infection
    BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .
    BRD9185
  • HY-145912
    RYL-552S

    		Parasite Infection Inflammation/Immunology
    RYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro .
    RYL-552S
  • HY-116736
    BRD7539

    		Dihydroorotate Dehydrogenase Parasite Infection
    BRD7539 is a PfDHODH inhibitor (IC50 = 0.033 μM). BRD7539 has potent activity against both multidrug-resistant asexual blood-stage (P. falciparum, Dd2 strain, EC50 = 0.010 μM) and liver-stage (P. berghei, EC50 = 0.015 μM) parasites .
    BRD7539
  • HY-148178
    MMV688533

    		Parasite Infection
    MMV688533 is an antimalarial agent. MMV688533 interferes with intracellular trafficking, lipid utilization, and endocytosis pathways in Plasmodium falciparum. MMV688533 rapidly kills asexual blood-stage Plasmodium falciparum and Plasmodium vivax parasites in vitro and reduces parasitemia in a Plasmodium falciparum NSG mouse model. MMV688533 can be used for the research of malaria .
    MMV688533
  • HY-161984
    HDAC-IN-76

    		HDAC Infection Others
    HDAC-IN-76 (compound 6i) is a histone deacetylase (HDAC) inhibitor. HDAC-IN-76 IC50 values of 30 nM and 98 nM for Pf3D7 (chloroquine (HY-17589A) drug-susceptible strain) and PfDd2 (chloroquine (HY-17589A) drug-resistant strain), has a highly potent antimalarial activity against asexual blood-stage Plasmodium, respectively, and exhibits selective inhibition against parasites, with IC50 values of 7 nM and 9 nM for human HDAC1 and HDAC6, respectively, while inhibiting PfHDAC1 .
    HDAC-IN-76
  • HY-182683
    MMV085203

    		Parasite TrxR Reactive Oxygen Species (ROS) Infection
    MMV085203 is a potent Plasmodium falciparum inhibitor, with a PfTrxR EC50 of 900 nM. MMV085203 exerts potent antimalarial activity against both blood‑stage and sexual‑stage Plasmodium falciparum parasites, with superior efficacy toward clinical isolates of high clonal diversity. MMV085203 modulates parasite redox homeostasis, induces ROS production, and elevates mitochondrial TCA cycle intermediates. MMV085203 can be used for the research of malaria .
    MMV085203
  • HY-182309
    SC83288

    		DNA Methyltransferase Parasite Infection
    SC83288 is a Plasmodium falciparum PfDNMT2 inhibitor with an IC50 of 7 μM. SC83288 disrupts the epigenetic regulation of malaria parasites, blocks DNA replication and nuclear division, arrests the development of the asexual blood stage, induces the formation of pyknotic morphology in malaria parasites, and does not affect cytokinesis after nuclear division or parasite egress. SC83288 is applicable to malaria-related research .
    SC83288
  • HY-182685
    MMV693183

    		Acetyl-CoA synthetase Parasite Infection
    MMV693183 is an orally active inhibitor of Plasmodium falciparum acetyl-CoA synthetase (AcAS), with an IC50 of 300 nM against Plasmodium falciparum. MMV693183 exhibits potent inhibitory activity against clinical isolates of malaria parasites, including Artemisinin (HY-B0094)-resistant strains. MMV693183 is metabolized in vivo into the active antimetabolite CoA-MMV693183, which exerts effects of killing asexual blood-stage parasites and blocking transmission to Anopheles mosquitoes by binding to and inhibiting the function of acetyl-CoA synthetase, thereby reducing the levels of acetyl-CoA and 4'-phosphopantetheine. In humanized mouse models, MMV693183 shows favorable in vivo efficacy, drug-like properties, and no significant cytotoxicity or off-target activity against human cells. MMV693183 is widely used in malaria-related research as a parasiticide and metabolic disruptor .
    MMV693183
  • HY-108024AR
    Ganaplacide hydrochloride (Standard)

    KAF156 hydrochloride (Standard); GNF156 hydrochloride (Standard)

    		 Reference Standards Parasite Infection
    Ganaplacide hydrochloride (Standard) is the analytical standard of Ganaplacide (hydrochloride) (HY-108024A). This product is intended for research and analytical applications. Ganaplacide (KAF156) hydrochloride is a first-in-class, orally active imidazolopiperazine antimalarial agent. Ganaplacide hydrochloride is active against a broad range of Plasmodium species, including drug-resistant parasites. Ganaplacide hydrochloride is parasiticidal against both asexual and sexual blood stages as well as the liver stages of the parasite .
    Ganaplacide hydrochloride (Standard)
  • HY-183238
    Antimalarial agent 61

    		Parasite Infection
    Antimalarial agent 61 is an antimalarial agent. Antimalarial agent 61 disrupts hemoglobin breakdown in Plasmodium falciparum asexual blood stage trophozoites. Antimalarial agent 61 exerts antiplasmodial activity against Chloroquine (HY-17589A)-sensitive Plasmodium falciparum parasites. Antimalarial agent 61 can be used for the research of malaria .
    Antimalarial agent 61
  • HY-18746
    KAI-407

    		Parasite PI4K Infection
    KAI-407 is an orally active inhibitor of Plasmodium PI4K kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC50s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC50s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria .
    KAI-407
  • HY-181821
    MMV1581361

    		Parasite Na+/K+ ATPase Infection
    MMV1581361 is a PfATP4 inhibitor and an orally active, transmission-blocking agent with nanomolar activity against Plasmodium falciparum blood-stage isolates. MMV1581361 disrupts sodium ion (Na +) homeostasis in Plasmodium falciparum. MMV1581361 inhibits male gamete exflagellation, reduces oocyst intensity, and blocks transmission of Plasmodium falciparum. MMV1581361 demonstrates efficacy in the humanized Plasmodium falciparum NOD scid IL2Rγ null mouse model. MMV1581361 can be used for the research of malaria .
    MMV1581361

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: